The University of Southampton
University of Southampton Institutional Repository

Pumactant abolishes early asthmatic response in patients with allergic asthma

Pumactant abolishes early asthmatic response in patients with allergic asthma
Pumactant abolishes early asthmatic response in patients with allergic asthma
Rationale: It is postulated that there exists a physical barrier in the lung which prevents the interaction of inhaled allergen with the epithelial lining of the airways and endogenous surfactant is a constituent of this barrier. Pulmonary surfactant abnormalities have been observed in asthmatic subjects and allergen challenge induces alteration in endogenous surfactant. The aim of the present study was to evaluate the effect of an exogenous surfactant on the early and late asthmatic responses (EAR & LAR).
Methods: Randomized, single-blind, cross-over study. Seven, mild, allergic asthmatic subjects (18-60 yr) with an EAR and LAR to a specific inhaled allergen were enrolled. The active treatment involved 2 doses of 400mgs of pumactant (respirable dose 100mg as a novel dry powder inhalation-dipalmitoylphosphatidylcholine and unsaturated phosphatidyl glycerol) given at 8 and 0.5 hrs prior to allergen BPT through an administration device. The placebo treatment involved exactly the same procedure but empty vials were used instead. The 2 treatment days were separated by 3 weeks.
Results: Pumactant abolished the EAR in all 7 subjects. The mean AUC for 0-2 hours following BPT was 0.08 (SEM=1.66) for pumactant and 13.29 (SEM=4.28) with placebo (p=0.006). The mean AUC for 3-10 hours with pumactant was 11 (SEM=4.51) and 17.35 (SEM=3.40) for placebo (p=0.16). The mean percentage reduction in FEV1 for the early response was 4.19% with pumactant and 29.68% with placebo (p<0.001). Pumactant was well tolerated with no adverse events.
Conclusions: This is the first study to demonstrate the effect of pumactant in blocking the EAR in allergen induced asthma. Pumactant could prove an effective therapeutic target in the management of asthma.
1073-449X
p.A216
Babu, K. S.
f63cb870-e593-48df-841a-4202320b6aba
Woodcock, D.
37432b2f-fc12-48ca-9d39-497598b92bc9
Smith, S. E.
b2db223b-6c6b-47a7-a2be-353f6782aac5
Heminsley, A. M.
85c23482-fe18-4532-a5db-536bbea4884b
Little, L.
41f55532-898e-41a6-97c6-2802a379d684
Staniforth, J. N.
301c6e65-a7ac-45eb-8916-399c86870308
Holgate, S. T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Conway, J. H.
bbe9a2e4-fb85-4d4a-a38c-0c1832c32d06
Babu, K. S.
f63cb870-e593-48df-841a-4202320b6aba
Woodcock, D.
37432b2f-fc12-48ca-9d39-497598b92bc9
Smith, S. E.
b2db223b-6c6b-47a7-a2be-353f6782aac5
Heminsley, A. M.
85c23482-fe18-4532-a5db-536bbea4884b
Little, L.
41f55532-898e-41a6-97c6-2802a379d684
Staniforth, J. N.
301c6e65-a7ac-45eb-8916-399c86870308
Holgate, S. T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Conway, J. H.
bbe9a2e4-fb85-4d4a-a38c-0c1832c32d06

Babu, K. S., Woodcock, D., Smith, S. E., Heminsley, A. M., Little, L., Staniforth, J. N., Holgate, S. T. and Conway, J. H. (2002) Pumactant abolishes early asthmatic response in patients with allergic asthma. American Journal of Respiratory and Critical Care Medicine, 165 (Supplement), p.A216.

Record type: Article

Abstract

Rationale: It is postulated that there exists a physical barrier in the lung which prevents the interaction of inhaled allergen with the epithelial lining of the airways and endogenous surfactant is a constituent of this barrier. Pulmonary surfactant abnormalities have been observed in asthmatic subjects and allergen challenge induces alteration in endogenous surfactant. The aim of the present study was to evaluate the effect of an exogenous surfactant on the early and late asthmatic responses (EAR & LAR).
Methods: Randomized, single-blind, cross-over study. Seven, mild, allergic asthmatic subjects (18-60 yr) with an EAR and LAR to a specific inhaled allergen were enrolled. The active treatment involved 2 doses of 400mgs of pumactant (respirable dose 100mg as a novel dry powder inhalation-dipalmitoylphosphatidylcholine and unsaturated phosphatidyl glycerol) given at 8 and 0.5 hrs prior to allergen BPT through an administration device. The placebo treatment involved exactly the same procedure but empty vials were used instead. The 2 treatment days were separated by 3 weeks.
Results: Pumactant abolished the EAR in all 7 subjects. The mean AUC for 0-2 hours following BPT was 0.08 (SEM=1.66) for pumactant and 13.29 (SEM=4.28) with placebo (p=0.006). The mean AUC for 3-10 hours with pumactant was 11 (SEM=4.51) and 17.35 (SEM=3.40) for placebo (p=0.16). The mean percentage reduction in FEV1 for the early response was 4.19% with pumactant and 29.68% with placebo (p<0.001). Pumactant was well tolerated with no adverse events.
Conclusions: This is the first study to demonstrate the effect of pumactant in blocking the EAR in allergen induced asthma. Pumactant could prove an effective therapeutic target in the management of asthma.

Full text not available from this repository.

More information

Published date: 2002
Additional Information: Conference Poster Abstract in American Thoracic Society Annual Meeting, 17-22 May 2002, Atlanta, Georgia, USA
Organisations: Health Profs and Rehabilitation Sciences

Identifiers

Local EPrints ID: 17793
URI: http://eprints.soton.ac.uk/id/eprint/17793
ISSN: 1073-449X
PURE UUID: fd5b3dec-182c-43bd-af5d-79e8482c7f12
ORCID for J. H. Conway: ORCID iD orcid.org/0000-0001-6464-1526

Catalogue record

Date deposited: 13 May 2009
Last modified: 22 Jul 2020 16:35

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×